Details

Autor(en) / Beteiligte

• Rein, D.T.
• Kurbacher, C.M.
• Breidenbach, M.
• Schöndorf, T.
• Schmidt, T.
• König, E.
• Göhring, U.-J.
• Blohmer, J.-U.
• Mallmann, P.

Titel

Weekly Carboplatin and Docetaxel for Locally Advanced Primary and Recurrent Cervical Cancer: A Phase I Study

Ist Teil von

• Gynecologic oncology, 2002-10, Vol.87 (1), p.98-103

Ort / Verlag

San Diego, CA: Elsevier Inc

Erscheinungsjahr

2002

Link zum Volltext

Quelle

Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

Beschreibungen/Notizen

• Objective. The aim of this study was to determine the dose-limiting toxicities (DLTs) and maximum tolerated doses (MTDs) of a docetaxel–carboplatin regimen in patients with locally advanced cervical cancer (LACC) or recurrent cervical cancer. The regimen was administered weekly, with a maximum of 12 courses. Patients and methods. Twenty patients were treated with with a total of 145 cycles of weekly carboplatin and docetaxel. The starting dose of docetaxel was 25 mg/m 2 with increments of 5 mg/m 2 until a final dose of 35 mg/m 2 was reached. Dose–escalation of docetaxel was followed by carboplatin at AUC 2, AUC 2.5, and AUC 3, respectively. Defined dose-limiting toxicities were WHO grade (G) 3 hematotoxicity, G4 mucositis, and G2 neurotoxicity. The response status of the patients was assessed using the common ECOG response criteria. Results. Two of four patients developed a DLT at dose level 4. Nonhematological toxicity was generally mild, except for ubiquitous complete alopecia. The MTD was reached at docetaxel 35 mg/m 2 and carboplatin AUC 2 mg/mL · min. The overall response rate was 65% in the entire group of evaluable patients and 77% in patients with primary LACC, with two cases of pathological complete response. Conclusion. This dose-dense regimen was well-tolerated and could be administered on an outpatient basis.